Orient Pharma Co., Ltd. (TPEX:4166)

Orient Pharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	575.25	587.6	84.5	83.32	76.43	130.92
Short-Term Investments	9.8	39.8	24.8	29.8	20.8	20.8
Cash & Short-Term Investments	585.05	627.4	109.3	113.12	97.23	151.72
Cash Growth	175.22%	474.04%	-3.38%	16.34%	-35.92%	-20.30%
Accounts Receivable	275.89	248.52	278.18	179.31	69.39	63.09
Other Receivables	12.51	16.38	10.36	8.16	12.91	16.82
Receivables	288.4	264.89	288.54	187.47	82.3	79.9
Inventory	327.08	322.39	279.56	233.97	194.18	156.88
Prepaid Expenses	47.86	26.46	44.12	58	39.18	30.91
Other Current Assets	29.26	18	6.91	29.7	10.24	19.89
Total Current Assets	1,278	1,259	728.43	622.25	423.12	439.31
Property, Plant & Equipment	805.6	835.58	891.83	944.96	903.28	769.71
Long-Term Investments	113.33	12.83	13.65	1.88	3.05	1.75
Other Intangible Assets	383.97	414.87	471.83	532.66	11.9	13.75
Long-Term Deferred Tax Assets	335.55	362.29	397.98	451.46	452.04	439.2
Other Long-Term Assets	95.83	53.65	16.87	9.47	54.18	100.1
Total Assets	3,012	2,938	2,521	2,563	1,848	1,764

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	52.01	62.07	36.14	55.57	61.97	19.6
Accrued Expenses	74.97	83.89	69.82	62.04	53.5	59.07
Short-Term Debt	-	-	250	314.5	68.5	161.5
Current Portion of Long-Term Debt	-	-	40	60.71	24.08	23.83
Current Portion of Leases	16.23	16.14	18.44	17.95	14.92	8.22
Current Unearned Revenue	23.6	4.47	64.51	22.01	64.87	78.07
Other Current Liabilities	5.99	20.54	8.35	30.56	63.22	69.17
Total Current Liabilities	172.8	187.1	487.25	563.35	351.06	419.46
Long-Term Debt	-	-	42.1	112.06	178.79	111.8
Long-Term Leases	173.28	179.81	195.95	211.67	221.86	109.67
Pension & Post-Retirement Benefits	6.9	6.81	5.86	5.09	5.94	6.85
Long-Term Deferred Tax Liabilities	0.93	1.15	1.84	-	-	0.13
Total Liabilities	353.9	374.88	733	892.18	757.65	647.9

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	2,430	2,430	2,230	2,230	1,870	1,870
Additional Paid-In Capital	128.04	369.05	1,130	1,130	932.15	932.15
Retained Earnings	96.15	-241.01	-1,579	-1,686	-1,709	-1,682
Comprehensive Income & Other	3.48	5.08	6.05	-3.83	-2.89	-4.6
Shareholders' Equity	2,658	2,563	1,788	1,670	1,090	1,116
Total Liabilities & Equity	3,012	2,938	2,521	2,563	1,848	1,764

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	189.51	195.95	546.49	716.9	508.15	415.01
Net Cash (Debt)	395.54	431.45	-437.19	-603.78	-410.92	-263.29
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	1.64	1.87	-1.96	-2.71	-2.20	-1.41
Filing Date Shares Outstanding	243.04	223.04	223.04	223.04	187	187
Total Common Shares Outstanding	243.04	223.04	223.04	223.04	187	187
Working Capital	1,105	1,072	241.18	58.9	72.07	19.86
Book Value Per Share	10.94	11.49	8.01	7.49	5.83	5.97
Tangible Book Value	2,274	2,149	1,316	1,138	1,078	1,102
Tangible Book Value Per Share	9.36	9.63	5.90	5.10	5.76	5.89
Buildings	797.07	796.79	794.16	786.78	744.9	682.91
Machinery	458.23	454.15	439.37	430.96	367.95	361.11

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 7, 2026

Data Sources Report a data error